MX9305901A - Factor-4 plaquetario modificado, factor-4 plaquetario de ruptura y procedimiento para la preparacionde los mismos. - Google Patents

Factor-4 plaquetario modificado, factor-4 plaquetario de ruptura y procedimiento para la preparacionde los mismos.

Info

Publication number
MX9305901A
MX9305901A MX9305901A MX9305901A MX9305901A MX 9305901 A MX9305901 A MX 9305901A MX 9305901 A MX9305901 A MX 9305901A MX 9305901 A MX9305901 A MX 9305901A MX 9305901 A MX9305901 A MX 9305901A
Authority
MX
Mexico
Prior art keywords
factor
mpf
platelet
platelet factor
cpf
Prior art date
Application number
MX9305901A
Other languages
English (en)
Inventor
Shalley Kant Gupta
Jai Pal Singh
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX9305901A publication Critical patent/MX9305901A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La presente invención se basa en el descubrimiento de dos formas modificadas del factor-4 plaquetario humano, aquí denominadas MPF-4 y CPF-4, que se aíslan de un medio de cultivo libre de suero de leucocitos periféricos sanguíneos estimulados por lipopolisacáridos. La determinación de la secuencia de aminoácidos revela que el MPF-4 3 es homólogo con el factor-4 plaquetario empezando en el resto N-terminal 17. El CPF-4 consiste en MPF-4 unido por puentes disulfuro a los 16 restos N-terminales del factor-4 plaquetario. El MPF-4 y el CPF-4 son ambos potentes inhibidores de la proliferación de células endoteliales, aproximadamente 10-100 veces más potentes que el factor-4 plaquetario natural o recombinante, lo que les hace útiles en el tratamiento de enfermedades angiogénicas.
MX9305901A 1992-09-25 1993-09-24 Factor-4 plaquetario modificado, factor-4 plaquetario de ruptura y procedimiento para la preparacionde los mismos. MX9305901A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95279792A 1992-09-25 1992-09-25

Publications (1)

Publication Number Publication Date
MX9305901A true MX9305901A (es) 1994-05-31

Family

ID=25493243

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9305901A MX9305901A (es) 1992-09-25 1993-09-24 Factor-4 plaquetario modificado, factor-4 plaquetario de ruptura y procedimiento para la preparacionde los mismos.

Country Status (24)

Country Link
US (3) US5512550A (es)
EP (1) EP0589719B1 (es)
JP (1) JPH06220091A (es)
KR (1) KR940007059A (es)
CN (1) CN1035257C (es)
AT (1) ATE151777T1 (es)
AU (1) AU665114B2 (es)
BR (1) BR9303903A (es)
CA (1) CA2106629A1 (es)
CZ (1) CZ195193A3 (es)
DE (1) DE69309827T2 (es)
DK (1) DK0589719T3 (es)
ES (1) ES2101237T3 (es)
FI (1) FI934183A7 (es)
GR (1) GR3023356T3 (es)
HK (1) HK100597A (es)
HU (1) HUT69928A (es)
IL (1) IL107040A0 (es)
MX (1) MX9305901A (es)
MY (1) MY109158A (es)
NO (1) NO933423L (es)
NZ (1) NZ248724A (es)
YU (1) YU61893A (es)
ZA (1) ZA936925B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107040A0 (en) * 1992-09-25 1993-12-28 Lilly Co Eli Modified platelet factor-4
CA2148301A1 (en) * 1994-05-09 1995-11-10 Rama Belagaje Expression of recombinant mpf-4, cpf-4, pf-4 and precursor compounds
US5994292A (en) * 1995-05-31 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
JPH09143199A (ja) * 1995-11-17 1997-06-03 Nippon Chem Res Kk 血小板第４因子の製造方法
CN100389126C (zh) * 1995-12-13 2008-05-21 儿童医学中心公司 内皮细胞增殖抑制剂及其应用方法
FR2774990B1 (fr) * 1998-02-16 2000-07-28 Inst Vaisseaux Et Du Sang Nouveaux peptides, utilisation en therapeutique et compositions pharmaceutiques les renfermant
CZ307433B6 (cs) 2001-09-12 2018-08-22 Leadiant Biosciences Sa Deriváty částečně desulfátovaných glykosaminoglykanů jako inhibitory heparanázy mající antiangiogenní účinky a zabraňující antikoagulačnímu působení
US20090011981A1 (en) * 2004-09-15 2009-01-08 K.U. Leuven Research & Development Novel Inhibitors of Angiogenesis
CN114805536B (zh) * 2022-06-24 2022-09-02 北京百臻生物技术有限公司 一种人血小板因子4蛋白突变体及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645828A (en) * 1984-03-23 1987-02-24 Oncogen Platelet related growth regulator
US4737580A (en) * 1985-03-15 1988-04-12 Oncogen Platelet related growth regulator
US4844895A (en) * 1985-11-01 1989-07-04 New York University Composition containing a peptide fragment of platelet factor four and method for restoring suppressed immune responses
NZ218634A (en) * 1985-12-20 1991-06-25 Oncogen Peptide identified by its cross reactivity with a cell growth factor, dna, antibodies to peptide and test kits
AU1539188A (en) * 1987-05-04 1988-11-10 Bristol-Myers Squibb Company TGF-B2 and novel compositions having anti-neoplastic activity
US5086164A (en) * 1989-01-10 1992-02-04 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
US5187075A (en) * 1989-01-26 1993-02-16 Sri International Cloning and expression of a variant gene of platelet factor 4 and compositions thereof to modulate immune responses
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
EP0423641A3 (en) * 1989-10-18 1992-01-15 Nippon Mining Company Limited Expression vector, transformed microorganism, fusion protein and method for the production of platelet factor 4 or tgfalpha
WO1992002240A2 (en) * 1990-07-27 1992-02-20 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
IL107040A0 (en) * 1992-09-25 1993-12-28 Lilly Co Eli Modified platelet factor-4

Also Published As

Publication number Publication date
EP0589719B1 (en) 1997-04-16
US5935928A (en) 1999-08-10
HK100597A (en) 1997-08-08
DE69309827T2 (de) 1997-08-28
DK0589719T3 (da) 1997-09-08
NO933423D0 (no) 1993-09-24
KR940007059A (ko) 1994-04-26
AU665114B2 (en) 1995-12-14
NO933423L (no) 1994-03-28
MY109158A (en) 1996-12-31
US5512550A (en) 1996-04-30
GR3023356T3 (en) 1997-08-29
US5538949A (en) 1996-07-23
BR9303903A (pt) 1994-06-14
FI934183L (fi) 1994-03-26
YU61893A (sh) 1996-02-19
ATE151777T1 (de) 1997-05-15
CZ195193A3 (en) 1994-04-13
NZ248724A (en) 1995-10-26
CN1035257C (zh) 1997-06-25
FI934183A0 (fi) 1993-09-24
CA2106629A1 (en) 1994-03-26
JPH06220091A (ja) 1994-08-09
EP0589719A1 (en) 1994-03-30
FI934183A7 (fi) 1994-03-26
ES2101237T3 (es) 1997-07-01
ZA936925B (en) 1995-03-20
AU4757393A (en) 1994-03-31
IL107040A0 (en) 1993-12-28
HUT69928A (en) 1995-09-28
CN1088216A (zh) 1994-06-22
DE69309827D1 (de) 1997-05-22
HU9302687D0 (en) 1993-12-28

Similar Documents

Publication Publication Date Title
ES2062549T3 (es) Proteina anticoagulante.
ES2070322T3 (es) Polipeptidos biologicamente activos basados en las secuencias del factor de crecimiento de transformacion beta.
ES2094159T3 (es) Produccion de factor de crecimiento de celulas endoteliales vasculares.
ES2103305T3 (es) Produccion de inhibidor de interleuquina-1 humana recombinada.
ES2186670T3 (es) Derivados de prostaglandina para el tratamiento del glaucoma o la hipertension ocular.
ES2099158T3 (es) Tratamiento del rechazo de trasplantes o de enfermedades autoinmunitarias y complejo de la formula general x-pro-y-boropro asociada al mismo.
IT1144601B (it) Derivati della vinblastina procedimento per la loro preparazione e composizioni farmaceutiche contenenti tali derivati
ATE84798T1 (de) Transformierender wachstumsfaktor-beta.
FI946004A0 (fi) Lääketieteellisessä toimenpiteessä käytettävä trombiiniverifraktio
ES2188585T3 (es) Inhibidores de factores reguladores celulares y procedimientos para evitar o reducir la formacion de cicatrices.
ES2150983T3 (es) Productos proteicos bactericidas estables que incrementan la permeabilidad y composiciones farmaceuticas que los contienen.
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
ES2123134T3 (es) Peptidos biologicamente activos de dominios funcionales de la proteina bactericida aumentadora de la permeabilidad y usos de los mismos.
DK151687D0 (da) Aprotinin-homologe fremstillet ud fra en rekombinant vaert, fremgangsmaade, ekspressionsvektor og rekombinant vaert derfor og farmaceutisk anvendelse deraf
ES2054365T3 (es) Inhibicion de la via de la regla del n final en celulas vivas.
ATE63126T1 (de) Tetra- und penta-peptide mit der sequenz lysylarginyl-aspartyl, und ihre verwendung als antithrombotika.
MX9301535A (es) Material proteinaceo biologicamente activo aislado y purificado.
IT1212508B (it) Analoghi retro - invertiti dei penta - ed esapeptidi c - terminali della sostanza p. utili come vasodilatatori
MX9301675A (es) Composiciones que contienen peptidos para inducir tolerancia de las celulas t a un antigeno.
DE3880194D1 (de) Zyklisches antikoagulierendes peptid.
ES2101237T3 (es) Factor-4 plaquetario modificado.
DE69013011D1 (de) Bcrf1-proteine als inhibitoren von interferon-g(g).
DE69010294D1 (de) Verwendung von Antiprogestomimetika zur Stimulierung des Eisprungs.
ES548052A0 (es) Procedimiento para preparar peptidos
MX9206960A (es) Alboagreginas:agonistas de las plaquetas que se ligan a la glicoproteina ib de la membrana de las plaquetas

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees